Page 184 - CW E-Magazine (19-11-2024)

CPHI MILAN 2024

effi cacy. It has excellent fl owability,
ensuring effi cient production processes
and minimising downtime. The low
dust formation also promotes a cleaner
manufacturing environment.

According to Mr. Kähkönen, the
company’s MCC offerings have low
levels of nitrosamines, which is a huge
challenge in many pharmacopoeias.
Nitrosamine impurities may increase
able to produce MCC with the most ditional MCC production processes. the risk of cancer if people are exposed
environmentally friendly and energy- Based on the fi ndings of an indepen- to them above acceptable levels and
effi cient process available today,” said dent third-party study, the process over long periods of time.
Mr. Olli Kähkönen, CEO and co-founder achieves a signifi cant 81% reduction
of NBG. in greenhouse gas emissions compared “We invested a lot of time and
to traditional methods,” he added. effort in perfecting our MCC production
Featuring the world’s fi rst continu- to exceed the highest standards. We are
ous production line of up to 10,000 The AaltoCell technology-driven ready to connect with companies look-
tons of MCC annually, the company’s MCC production was also listed as ing for compounds and ingredients
Lappeenranta (Finland) facility, which one of the fi nalists at the CPHI Milan that can be traced all the way back to
was opened this year, is designed to Awards in the sustainability category. where they were sourced from,” said
ensure quality and purity in MCC pro- Mr. Kähkönen.
duction. NBG said its PURA Series pro-
vides a diverse selection of MCC In June this year, NBG had
“We have a strong background products tailored to the pharmaceutical received the EXCiPACT certifi cation
in cellulose chemistry, and we are industry. It has high compressibility for the production of MCC. EXCiPACT
focussed on sustainability and green and density that enables the produc- is an independent, nonprofi t associa-
chemistry,” said Mr. Kähkönen. “We tion of stronger, smaller tablets while tion that provides management over-
prioritise environmental sustainability optimising batch sizes. Additionally, sight for the third-party certifi ca-
by producing zero solid waste and us- the PURA Series has improved dis- tion of manufacturers, suppliers, and
ing only a fraction of the chemicals, integration, which facilitates optimal distributors of pharmaceutical excipients
water, and electricity compared to tra- release of active ingredients for better worldwide.

DERMO-PHARMACEUTICAL APPLICATION
Seppic launches new surfactant designed for

biological applications

Seppic, a France-based manu- in solution using specifi c excipients.
facturer of pharmaceutical exci- In response to this problem, Seppic
pients and a subsidiary of Air Liquide developed Montanox 20 HPB, a high
Healthcare, expanded its portfolio of purity polysorbate 20 suitable for the
injectable surfactants with the launch most sensitive active ingredients.
of Montanox 20 HPB. This new high-
purity non-ionic polysorbate has been According to Seppic, its formula is
developed for the formulation of bio- tailored to the needs of biopharmaceu-
logical drugs. lenges. To maintain their full effi cacy, tical formulators with stricter speci-
biological active ingredients, which fi cations on fatty acid distribution to
Biopharmaceuticals present many are more complex than those derived minimise the risk of active ingredient
advantages but also formulation chal- from chemistry, need to be stabilised degradation, offering improved bio-

184 Chemical Weekly November 19, 2024

Contents Index to Advertisers Index to Products Advertised